- Early-stage trials of a new immunotherapy drug, VIR-5500, for advanced prostate cancer have yielded "remarkable" results.
- The drug, a "T-cell engager," employs a unique "cloaking device" that ensures it only activates upon reaching the tumour site, significantly reducing adverse reactions.
- In trials involving 58 men with advanced prostate cancer resistant to other treatments, 45 per cent of 11 patients experienced tumour shrinkage.
- A high proportion of patients (88 per cent) reported only mild side effects, addressing a key challenge faced by traditional immunotherapies for prostate cancer.
- Researchers are optimistic that VIR-5500 could offer a new treatment option and potentially lead to a cure for advanced prostate cancer in the future.
IN FULL
